Read this company snapshot
Daily valuation snapshot
Adagene Inc. American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.76
- Market capitalization (USD)
- $163,480,300.68
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.15
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ADAG in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ADAG in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ADAG with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.76 |
| Market capitalization (USD) | $163,480,300.68 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.15 |
No matching rows. Clear the filter to see all records.
Read ADAG's valuation metrics
Company size
Adagene Inc. American Depositary Shares's recorded market capitalization is $163,480,300.68. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ADAG's recorded price-to-book ratio is 3.15. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Adagene Inc. American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about ADAG. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ADAG's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.